Reviewer's report

Title: A randomized, double-blind, placebo-controlled study of intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

Version: 1 Date: 18 August 2012

Reviewer: Rene Ernst Nielsen

Reviewer's report:

Dear authors,

Thank you very much for a well-written manuscript on a Japanese population of patients with schizophrenia treated with olanzapine IM.

• Major Compulsory Revisions
  None

• Minor Essential Revisions
  1) Page 5, line 3: “..should be sedated as soon as possible…”: The desired outcome of treatment of acute agitation is not sedation, but more a calming effect. The use of sedation as desired outcome should be changed.
  2) Page 6, line 2: Please provide reference for antipsychotic injections sedating patients faster than oral medications
  3) Page 7, lines 3-7: The sentence is non-sense. Please rephrase.
  4) Page 9, line 14: Please clarify injection site (gluteal ?)
  5) Page 16, line 12: Please provide p-value for 24-hour PANSS-EC score in the manuscript
  6) Page 17, line 11: Please provide p-value for difference in need of second injection between groups
  7) Page 19, lines 9-10: Remove understrike

• Discretionary Revisions
  8) Page 8, lines 1-3: You could provide data on distribution of patients in these three groups, for both placebo and olanzapine groups.
  9) Page 9, 6-9: You could provide data on the use of benzodiazepines in each treatment arm

Level of interest: An article whose findings are important to those with closely related research interests
Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

R. Ernst Nielsen has received research grants from H. Lundbeck for clinical trials, received speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen & Cilag, Lundbeck and has acted as advisor to Astra Zeneca.